

12-8062: Anti-Human DR5 (Drozitumab) - DyLight® 488

Clonality :	Monoclonal
Clone Name :	PRO95780
Application :	Functional Assay
Reactivity :	Human
Alternative Name :	DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5
Isotype :	Human IgG1lambda
Immunogen Information :	DR5 scFv

Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only.

Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.¹ Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.

Product Info

Amount :	100 µg Concentration : 0.2 mg/ml
Content :	This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 µg per 10⁶ cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.